FDA Approves Tablet Form of Evrysdi for Spinal Muscular Atrophy

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 18, 2025.

By Lori Solomon HealthDay Reporter

TUESDAY, Feb. 18, 2025 -- The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

The new tablet is expected to be available in the coming weeks and is suitable for people aged 2 years and older who weigh more than 44 lbs.

The approval of the Evrysdi tablet was based on the results of a bioequivalence study, which demonstrated that the 5-mg tablet, either swallowed whole or dispersed in filtered water, provided comparable exposure to the original oral solution of Evrysdi. The Evrysdi oral solution will remain available for those on other doses of Evrysdi and for those who may prefer the oral solution.

"We cannot underestimate the value that comes with simplifying treatment administration and disease management for people who are living with SMA or those caring for them," Kenneth Hobby, president of Cure SMA, said in a statement. "This new room temperature stable formulation option offers an additional choice that may more conveniently fit into daily living activities such as working, traveling, and education."

Approval of Evrysdi was granted to Genentech.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-19 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords